Medidata expands its ability to provide eCOA quickly and flexibly in the Japanese market through domestic major CRO partner EPS becoming the first in Japan to obtain the "myMedidata eCOA Accreditation" qualification

▤ Summary

Medidata and EPS expanded their partnership after EPS became the first domestic CRO in Japan to earn the myMedidata eCOA Accreditation. The accreditation lets EPS build and operate Medidata eCOA more quickly and flexibly for Japanese, Asia, and global clinical trials. The release says the new setup can cut build timelines from about four months to as little as two months while also improving cost efficiency. The deal strengthens localized support for patient-centered trials and should help sponsors move studies forward faster in Japan.

▦ Linked Companies

Medidata

$500M to $1B